# What is the wolverine peptide stack?

Updated October 17, 2026. Source: https://whatisthewolverinepeptidestack.com/

## Short answer

The wolverine stack is two lab-made peptides, **BPC-157** and **TB-500**, used together in hopes of faster recovery from muscle, tendon and other tissue injuries.[1][2] It is not FDA-approved, and most of the evidence comes from animal and lab studies, with only a few tiny human reports.[1][2][3] Both peptides are banned in sport.[15]

## Quick fit check

If any of these apply, mention them in the assessment:

- **You compete in a drug-tested sport:** WADA bans BPC-157 and TB-500 at all times, and athletes are strictly liable for what is in their systems.[15][17] USADA says a therapeutic use exemption for BPC-157 is unlikely to be approved.[16]
- **You want an FDA-approved treatment:** The stack is not FDA-approved, and USADA says BPC-157 is not approved for human use by FDA or any other health authority. A provider will weigh this.[1][16]
- **You have a history of cancer or precancerous cells:** Some peptides promote new blood vessel growth, which could in theory feed a tumor, and no human safety trials have tested this. A provider will weigh this history.[1]
- **You have reacted to a peptide injection before:** FDA has flagged a risk that injected forms of both peptides could trigger immune reactions. A provider will weigh any past reaction.[6][7]
- **You were planning to buy peptides sold online as research chemicals:** Products sold as research chemicals come with no guarantee of what is in the vial.[11] FDA has said “research purpose only” labels do not stop such products from being unapproved drugs.[14]

## Key facts

- **What's in it:** BPC-157, a 15 amino acid peptide, plus TB-500, a 7 amino acid fragment of thymosin beta-4.[6][7][8]
- **What people use it for:** Hoped-for faster healing of muscle, tendon and other soft-tissue injuries. These are claims, not proven benefits.[1][2]
- **FDA status:** Not FDA-approved. FDA advisers voted in July 2026 to recommend allowing pharmacy compounding, but the vote is non-binding.[1][11]
- **Evidence base:** Mostly animal and lab studies. A 2026 review found 3 small human studies of BPC-157 with 30 people in total, all of poor quality.[2][3]
- **In sport:** Banned at all times by the World Anti-Doping Agency: BPC-157 under S0 and TB-500 under S2.[15]
- **How it is usually taken:** Usually injected under the skin or into a muscle, often from products sold for “research purposes.”[1]

## Regulatory timeline

| Date | What happened |
| --- | --- |
| June 12, 2023 | An FDA warning letter called products labeled BPC-157 and TB-500 unapproved new drugs, despite “research purpose only” labels.[14] |
| January 1, 2026 | The 2026 WADA Prohibited List takes effect, naming BPC-157 under S0 and TB-500 under S2.[15] |
| July 23, 2026 | FDA’s compounding advisory committee votes 8 to 6, with 1 abstention, to recommend adding BPC-157, TB-500 and KPV to the 503A bulks list.[12] |
| October 14, 2026 | White House regulatory reviewers receive an FDA interim access policy for compounding certain peptides. Its text and covered peptides are not public.[13] |
| January 1, 2027 | The 2027 WADA Prohibited List takes effect. BPC-157 and TB-500 remain prohibited.[17] |

## What's in it

- **BPC-157:** A synthetic peptide made to match part of a “body protection compound” first found in human stomach juice.[16] FDA describes it as a peptide of 15 amino acids.[6]
- **TB-500:** A short synthetic peptide of 7 amino acids that FDA lists as a fragment of thymosin beta-4.[7][8] FDA notes that “TB-500” is a common name, not an official drug name, so a product may not contain the substance a prescriber intended.[7]
- **The “stack”:** Stacking means using more than one peptide at the same time.[1] Human data on this pair is limited to a 2021 chart review in which 4 people got knee injections of BPC-157 combined with thymosin beta-4, and 3 reported improvement.[2][4]

## What the evidence shows

- **Animal and lab studies:** A 2025 systematic review found 36 studies of BPC-157 in sports medicine: 35 preclinical and 1 clinical.[3] In animal models, BPC-157 improved healing of muscle, tendon, ligament and bone injuries.[3] A 2026 review of sports medicine peptides, including BPC-157 and TB-500, found that many unapproved peptides do well in animal models but rigorous human safety data are scarce.[5]
- **Human studies of BPC-157:** A 2026 systematic review found 3 human studies with 30 people in total: a knee pain chart review (16 people), a bladder pain pilot (12) and an intravenous safety pilot (2).[2] All 3 were judged poor quality, and the review rated the overall certainty of evidence as very low.[2]
- **Human studies of TB-500:** FDA found no clinical studies or human exposure data for TB-500 by any route.[7]
- **FDA’s own review:** In its July 2026 briefing documents, FDA staff found a lack of evidence of effectiveness and proposed not adding either peptide to the compounding list.[6][7]

## Legal and regulatory status

- **Not approved:** The stack is not FDA-approved.[1] USADA says BPC-157 is not approved for human clinical use by FDA or any other global health authority.[16]
- **Compounding rules:** Under section 503A, pharmacies may compound only with bulk substances that have a USP or NF monograph, are part of an FDA-approved drug, or appear on FDA’s 503A bulks list.[9] As of August 2026, USADA said there was no legal basis to include BPC-157 in any compounded medication.[16]
- **FDA safety list:** FDA lists BPC-157 and TB-500 among substances that were previously in its “category 2” of potential significant safety risks and whose nominations were withdrawn.[8]
- **July 2026 advisory vote:** FDA’s Pharmacy Compounding Advisory Committee voted to recommend adding both peptides to the 503A bulks list, against FDA staff’s recommendation.[11][12] Advisory committee votes are non-binding, and FDA must still review the record and publish proposed rules before anything becomes official.[10][11]
- **Pending interim policy:** On October 14, 2026, White House regulatory reviewers received an FDA “Interim Access Policy for Compounding Using Certain Peptides,” listed as pending review.[13] The public record does not disclose which peptides it covers or its conditions.[13]
- **Selling as “research” chemicals:** FDA has warned that “research purpose only” labels do not stop products from being treated as drugs for human use.[14]

## Risks and unknowns

- **Unknown safety in people:** FDA says it lacks enough information to know whether BPC-157 or TB-500 would cause harm in humans.[8]
- **Immune reactions:** FDA is concerned that injected forms of both peptides could trigger immune reactions, partly because of clumping and peptide-related impurities.[6][7]
- **Product quality:** Many people buy these compounds online as unregulated “research chemicals,” with no doctor involved and no guarantee of what is in the vial.[11] Injecting a product made in unverified conditions carries a risk of infection or contamination.[1]
- **Reported side effects:** Anecdotal reports include injection site irritation, stomach upset, tiredness and headaches.[1] FDA’s adverse event database held three reports for injected BPC-157, including an injection site reaction, shortness of breath, and darkening of the skin and gums.[6]
- **Animal safety signals:** In 28-day studies, BPC-157 injected into muscle in rats and dogs was linked to changes in blood clotting tests and liver-related lab values.[6]
- **Cancer question:** Because some peptides work by promoting new blood vessel growth, they could in theory feed blood vessels to a tumor in someone with precancerous cells. No human safety trials have tested this.[1]

## Common questions

### Does the wolverine stack work?

There is no good human evidence that it does, and a 2026 review rated the certainty of the human evidence as very low.[2] Animal studies of BPC-157 look promising, but the few human studies are tiny and of poor quality, and FDA found no human data for TB-500.[2][3][7]

### Is the wolverine stack safe?

Its safety in people is unknown.[8] FDA says it lacks enough information to know whether either peptide would cause harm in humans, and it has flagged risks such as immune reactions and impurities.[6][7][8]

### Is the wolverine stack legal?

It is not FDA-approved.[1] FDA advisers voted in July 2026 to recommend letting compounding pharmacies use BPC-157 and TB-500, but the vote is non-binding.[11][12] As of October 16, 2026, an FDA interim policy on compounding certain peptides was still under White House review, and state pharmacy rules also apply.[13]

### Is the wolverine stack banned in sports?

Yes. The 2026 WADA Prohibited List bans BPC-157 under S0 and thymosin beta-4 and its derivatives, such as TB-500, under S2, both at all times.[15] Both remain prohibited on the 2027 list.[17] USADA says a therapeutic use exemption for BPC-157 is unlikely to be approved.[16]

### Why is it called the wolverine stack?

The nickname refers to the Marvel character known for regenerative healing, based on the stack’s supposed regenerative effects.[1]

### How long does the wolverine stack take to work?

There is no reliable human data on timing.[2][7] The few human studies of BPC-157 were small and had no control group, and FDA found no human studies of TB-500.[2][7]

## Next step

**Talk to a provider about injury recovery.** Complete an online health assessment. A licensed provider reviews it and decides whether this stack or another option is appropriate for you.

What the assessment includes:

- Online health assessment
- Review by a licensed provider
- Shipped to you if prescribed
- Card held at checkout, charged only if prescribed

How to get started:

1. **Answer health questions.** An online assessment about your health, history and goals.
2. **A licensed provider reviews it.** They decide whether a prescription is safe and appropriate for you.
3. **If prescribed, it ships to you.** Your card is only held at checkout. You’re charged only if a provider prescribes.

Not everyone qualifies. A provider decides based on your health history.

Start the assessment: https://whatisthewolverinepeptidestack.com/go/md/agent

Assessments are completed with a partner telehealth provider. This site may earn a commission if you start one through it.

## Sources

1. What's in the Wolverine Peptide Stack? Research and Safety. Healthline (medically reviewed by Ami Patel, PharmD, BCPS). Updated October 14, 2026. https://www.healthline.com/health/wolverine-peptides
2. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety (Poolton JT, Minett J, Kazmi A). Acta Orthopaedica Belgica, via PubMed. October 8, 2026. https://pubmed.ncbi.nlm.nih.gov/42885452/
3. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (Vasireddi N, et al.). HSS Journal, via PubMed. July 31, 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
4. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (Lee E, Padgett B). Alternative Therapies in Health and Medicine, via PubMed. July 2021. https://pubmed.ncbi.nlm.nih.gov/34324435/
5. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Mendias CL, Awan TM). Sports Medicine, via PubMed. August 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
6. FDA Briefing Document: BPC-157-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. July 2026. https://www.fda.gov/media/193343/download
7. FDA Briefing Document: TB-500-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. July 2026. https://www.fda.gov/media/193349/download
8. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. Content current as of April 22, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
9. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration. Content current as of May 14, 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
10. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. Updated August 6, 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
11. FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?. ABC News. July 24, 2026. https://abcnews.com/Health/fda-advisers-narrowly-vote-add-6-peptides-drug/story?id=135064915
12. FDA Panel Backs 6 Peptides for Compounding. The American Journal of Managed Care (AJMC). Accessed October 17, 2026. https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
13. FDA Submits Interim Peptide Compounding Policy for White House Review: What Pharmacies Should Know. Buchanan Ingersoll & Rooney PC. October 16, 2026. https://www.bipc.com/fda-submits-interim-peptide-compounding-policy-for-white-house-review-what-pharmacies-should-know
14. Warning Letter: Warrior Labz SARMS, MARCS-CMS 655280. U.S. Food and Drug Administration. June 12, 2023. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/warrior-labz-sarms-655280-06122023
15. World Anti-Doping Code International Standard: Prohibited List 2026. World Anti-Doping Agency. In effect January 1, 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
16. BPC-157: What Athletes Should Know About the Prohibited Experimental Peptide. U.S. Anti-Doping Agency (USADA). Updated August 10, 2026. https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
17. Athlete Advisory: What's New on the 2027 WADA Prohibited List?. U.S. Anti-Doping Agency (USADA). October 6, 2026. https://www.usada.org/spirit-of-sport/athlete-advisory-2027-prohibited-list/

---

General education, not medical advice. Talk to a licensed clinician before starting or changing any medicine.